mAb lead optimization
Have a lead antibody, but need humanization or improvement of
affinity or function?
Speed up the development of high-impact monoclonal antibodies with our phage
display wizardry and dedication to optimization.
From discovery research to lead identification for therapeutics and diagnostics
development, we are the team who delivers the specificity, affinity, and functionality
few others can.
See how we uniquely pair rabbit immunization with phage display to deliver pM KD lead mAbs!
Larger libraries. Heightened affinity. Unique functionality.
By combining the versatility of phage display technology with the power of the rabbit immune response, our highly-engineered platform grants you access to even the rarest antibodies, fully optimized for your specific application by our team of experts.
Accelerate the development of therapeutic lead candidates with our end-to-end solutions. Every step of our process is fully optimized and tailored to deliver exactly what you need.
STEP 1
Immunization
STEP 2
Library
Construction
WizAmp™
STEP 3
Panning &
Screening
STEP 4
Recombinant
IgG production
STEP 5
Humanization
STEP 6
Affinity Maturation
and Optimization
Stem™
Have a target in mind, but need a therapeutic mAb developed
from scratch?
Have a lead antibody, but need humanization or improvement of
affinity or function?
Need a high affinity, highly specific mAb for detection to be
used in your assay of choice?
“With Abwiz, you get a bigger library, so you have more options to pick a good, high affinity antibody.”
“We chose Abwiz because we wanted something fast, and they're using phage display, so you can really select for the properties that you want”
One of the nice things when you go through Abwiz, is that you own the antibody free and clear. They don't charge you downstream royalties for your later development of a product.”
“Abwiz is willing to do a lot of optimization, they really do a lot of work, putting a lot of time on a project. And some other vendors I work with don't want to do anything extra to make our antibody.”
We are a group of former drug discovery scientists who wanted to revolutionize the way monoclonal antibodies are made, especially for tough targets.
From mAb lead discovery to humanization and optimization, we make rare monoclonal antibodies easily attainable.